Novanta closes $1.2B Riverpoint Medical acquisition, doubles recurring medical revenue

Filed July 27, 2026 · Period ending July 22, 2026 · ~1 min read

Key Changes

• high

  Closed acquisition of Riverpoint Medical for ~$1.2B cash plus $250M milestone due Jan 2027; funded with $616M debt and cash on hand, bringing total debt to $854.7M.

  Item 2.01, Item 2.03 verify on EDGAR →
• high

  Acquisition expected to double recurring medical consumables revenue to ~$300M and push medical end-market exposure to 60% of total revenue; Riverpoint growing revenue and cash flow at twice Novanta's rate.

  Exhibit 99.1 view on EDGAR →
• high

  Deal expected to contribute $0.18-$0.25 adjusted EPS in 2027, generate high single-digit ROIC by year three, and be immediately accretive to organic growth, adjusted gross margins, and cash flows.

  Exhibit 99.1 view on EDGAR →